Vishu Murthy, PhD

Clinical Chemistry Fellow, Department of Laboratory Medicine and Pathology

Vishu Murthy

Contact Info

Ph.D. (Physiology and Pharmacology), Wake Forest University School of Medicine, Winston Salem, NC, May 2008

M.B.A. (Business), Lebanon Valley College, Annville, PA, May 2011

Summary

  • 15 years of preclinical, translational and clinical research experience in top ranked academic institutions.
  • Expertise in Biochemistry, integrative Physiology and Pharmacology and Toxicology and trained ability to translate scientific research into disease settings through conception and development of new models,

    assays and tests.

  • Scientific and regulatory expertise in preclinical and clinical stages (Phase I-IV) of drug discovery and development (drugs and biologics from bench to bedside).  Played a vital role in discovering a novel drug for Symptomatic treatment of Parkinson’s disease andAlzheimer’s disease and Schizophrenia; parent molecule “dihydrexidine” in Phase II trial for 

    treatment of Schizophrenia and Phase I trial for treatment of cocaine addiction.? Initiated and managed a multidisciplinary collaborative preclinical therapeutic development program and advanced a biologic to treat cocaine addiction to first-in-human use.

  • International Certification in Clinical Research (CCRP) and Certified for GCP (Human Research)
  • Proven scientific track record (> 25 abstracts and publications and a book chapter; Ca. 500 citations)

Expertise

  • ELISA, Enzyme Assays, Ligand Binding Assays, Radio-immunoassays, Molecular functional assays, HPLC, Mass Spectrometry, RT-PCR, Western Blot, Immunoprecipitation.
  • Cell Culture (Cell Proliferation Assays, siRNA knock down and cDNA over-expression assays)
  • Rodent animal – Behavioral Pharmacology: real-time Cardiovascular safety and Toxicology, CNS Safety and

    Toxicology, real – time Physiology and Metabolic Assessments, CNS Stereotaxic surgeries.

Awards & Recognition


2016 - Identified and Interviewed for NIDA’s Hot Science Coverage in NIDA Notes - Promise and Progress of Cocaine Hydrolase Gene Therapy for the treatment of Cocaine Addiction

2015 - Co-Recipient of Indo-US Science and Technology Forum – Mayo Clinic – JSS University Symposium Award ($20,000)-Emerging Trends in Healthcare – Lessons from Clinical and Translational Research. 

2012 - Travel Award – Indo-US Bilateral Symposium on “Molecular Pharmacology and Applied Therapeutics” JSS Medical College, Mysore, India. (Award co-sponsored by the Indian council of Medical Research, Defence Research and Development Organization and JSS University)

2011 - Travel Award – Indo-US Bilateral Symposium on “Frontiers in Medicinal Chemistry and Drug Discovery” JSS Medical College, Mysore, India. (Award co-sponsored by the Indo-US Science and Technology Forum – American Chemical Society)

2010 - Outstanding Postdoctoral Award-III Place American Society for Pharmacology and Experimental Therapeutics (ASPET) Award won at the international Experimental Biology meeting (2010). Anaheim, CA

2009 - Alzheimer’s Drug Discovery Foundation (ADDF) Outstanding Young Investigator Travel Award Award presented at January 2009 international meeting of ADDF, Washington, DC
2004-2008 - CNAT Fellowship; Center for the Neurobiology of Addiction Treatment (CNAT), Wake Forest University School of Medicine, Winston-Salem, NC

Professional Associations

Society for Clinical Research Associates, 2018 - Present

American Association for Clinical ChemistryCertification: Professional Practice in Clinical Chemistry (2019), 2019 - Present

Research

Publications

  • V Murthy, S Reyes, L Geng, Y Gao and S Brimijoin. Cocaine hydrolase gene transfer is cardiac safe and effective against cocaine induced QT prolongation in mice. J Pharmacol Exp Ther. 2016 (PMCID: PMC4767396)
  • V Murthy, Y Gao, L Geng, and S Brimijoin. Reward and Toxicity of Cocaine Metabolites Generated by Cocaine Hydrolase. Cell Mol Neurobiol. 2015 (PMCID:PMC4617233)
  • V Murthy, Y Gao, L Geng, N LeBrasseur, T white and S Brimijoin. Physiologic and metabolic safety of butyrylcholinesterase gene therapy in mice. Vaccine. 2014 (PMCID:PMC4077905)
  • V Murthy, Y Gao, L Geng, N LeBrasseur, T white, and S Brimijoin. Preclinical studies on neurobehavioral and neuromuscular effects of cocaine hydrolase gene therapy in mice. J Mol. Neurosci. 2014 (PMCID: PMC3983183)